RecruitingRare disease

Study on the Effect and Safety of Autologous Mesoangioblasts for Patients with Mitochondrial Myopathy Due to m.3243A>G Mutation

Verified siteInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as G mutation, which leads to a disease called . This disease affects the muscles and can cause weakness and fatigue. The study will use a treatment involving , which are special cells derived from a patient's own muscle tissue. These cells are prepared as a and are also known by the code name .

The purpose of the study is to assess the effect and safety of administering these cells directly into the arteries of the upper arm in patients with the G mutation. The study will involve three administrations of the treatment to the left arm. Researchers will evaluate the strength and fatigue of the muscles in both arms before and after the treatment. They will also monitor for any serious side effects, blockages in blood vessels, and changes in neurological signs, which are indicators of the nervous system's health.

Throughout the study, participants will have their muscle strength and fatigue measured using a special device. Additionally, muscle samples will be taken to examine muscle mass, structure, the load of the G mutation, and the ability of the muscles to use oxygen. The study is expected to continue until June 2026, with recruitment starting in November 2023.

The research process

The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, eligibility is confirmed based on criteria such as age (18-64 years), gender (male or female), and presence of the m.3243A>G mutation.
Written informed consent is required to participate.
Step 2
Initial assessment
An initial assessment is conducted to evaluate muscle strength and fatigue in both arms using a device called a Biodex dynamometer.
Baseline measurements are taken before any treatment is administered.
Step 3
First administration
The first administration of autologous mesoangioblasts is performed via intra-arterial injection into the left upper arm.
This involves a cell suspension specifically prepared for injection.
Step 4
Monitoring after first administration
After the first administration, monitoring is conducted for 8 hours to check neurological vital signs and ensure no serious adverse events (SAEs) occur.
Angiography may be used to assess vascular conditions.
Step 5
Second administration
A second administration of the cell suspension is performed in the same manner as the first, targeting the left upper arm.
Step 6
Monitoring after second administration
Similar to the first administration, monitoring is conducted for 8 hours post-procedure to ensure safety and check for any adverse effects.
Step 7
Third administration
The third and final administration of the cell suspension is carried out, again targeting the left upper arm.
Step 8
Monitoring after third administration
Post-procedure monitoring is conducted for 8 hours to ensure safety and check for any adverse effects.
Step 9
Follow-up assessment
A follow-up assessment is conducted 4-6 weeks after the third administration to evaluate changes in muscle strength and fatigue using the Biodex dynamometer.
Muscle biopsies may be taken to assess muscle mass, morphology, mutation load, and mitochondrial respiratory capacity.

Who can join the trial?

4 criteria

The patient must provide written informed consent, which means they agree to participate in the study after being fully informed about it.
The patient must be between the ages of 18 and 64.
Both males and females can participate in the study.
The patient must have a specific genetic change called the m.3243A>G mutation, which is related to a condition affecting the muscles known as mitochondrial myopathy.

Who cannot join the trial?

4 criteria

Patients who do not have the m.3243A>G mutation, which is a specific change in the genetic material that can cause a condition called mitochondrial myopathy, cannot participate.
Patients who are not within the specified age range for the study cannot participate. The age range is not specified in the provided data, but it is important for eligibility.
Patients who are part of a vulnerable population, which means they might need special protection or care, are not included in the study.
Patients who have any other medical conditions or factors that the study team believes would make it unsafe or inappropriate for them to participate cannot join the study.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

University Hospital Maastricht
Verified
Maastricht, The Netherlands

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Autologous Myogenic Stem Cell Therapy is a treatment that uses stem cells derived from the patient's own body. In this trial, the therapy involves administering these stem cells directly into the arteries of the upper left arm. The goal is to improve muscle strength and reduce fatigue in patients with a specific genetic mutation known as m.3243A>G. The therapy is given three times, and its safety is monitored by checking for any serious adverse effects, blockages in blood vessels, and changes in neurological health.

Autologous Muscle Precursor Cells

What is already known about the treatment

Autologous Myogenic Stem Cell Therapy – This therapy is administered intra-arterially, specifically targeting the upper left arm. It is currently under investigation in clinical trials for its potential to treat mitochondrial myopathy caused by the m.3243A>G mutation. The main therapeutic indication is to improve muscle strength and reduce fatigue in affected individuals. At the molecular level, the therapy involves the use of autologous myogenic stem cells, which are believed to aid in muscle repair and regeneration. It falls under the pharmacological classification of advanced therapy medicinal products (ATMPs).

Investigated diseases

Mitochondrial Myopathy – This condition is caused by a genetic mutation known as m.3243A>G, which affects the mitochondria, the energy-producing structures within cells. It primarily impacts muscle cells, leading to muscle weakness and fatigue. As the disease progresses, individuals may experience increasing difficulty with physical activities due to the muscles' reduced ability to generate energy efficiently. The condition can also affect other systems in the body, depending on the extent of mitochondrial dysfunction. Symptoms can vary widely among individuals, even within the same family. The progression of the disease is often gradual, with symptoms worsening over time.